Hybrid capture II and PapilloCheck® tests for detection of anal high-risk human papillomavirus by Maia, Livia Bravo et al.












Este artigo está licenciado sob uma licença Creative Commons Atribuição-NãoComercial 3.0 
Unported. 
Você tem direito de: 
Compartilhar — copiar e redistribuir o material em qualquer suporte ou formato 
Adaptar — remixar, transformar, e criar a partir do material 
De acordo com os termos seguintes: 
Atribuição — Você deve dar o crédito apropriado, prover um link para a licença eindicar se 
mudanças foram feitas. Você deve fazê-lo em qualquer circunstância razoável, mas de maneira 
alguma que sugira ao licenciante a apoiar você ou o seu uso. 
NãoComercial — Você não pode usar o material para fins comerciais. 
Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter 




This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported 
License. 
You are free to: 
Share — copy and redistribute the material in any medium or format. 
Adapt — remix, transform, and build upon the material. 
Under the following terms: 
Attribution — You must give appropriate credit, provide a link to the license, and indicate if 
changes were made. You may do so in any reasonable manner, but not in any way that 
suggests the licensor endorses you or your use. 
NonCommercial — You may not use the material for commercial purposes. 
No additional restrictions — You may not apply legal terms or technological measures that 
legally restrict others from doing anything the license permits. 
 
Case Reportshort CommunicationRevista da Sociedade Brasileira de Medicina Tropical 47(2):227-230, Mar-Apr, 2014http://dx.doi.org/10.1590/0037-8682-0081-2012
Address to: Dra Fabiana Pirani Carneiro. Centro de Anatomia Patológica/HU/
UnB. Via L2 Norte, SGAN 604/605, 70840-050 Brasília, DF, Brasil.
Phone: 55 61 3448-5499
e-mail: fabianapirani@hotmail.com
Received 18 February 2013
Accepted 8 August 2013
Hybrid capture II and PapilloCheck® tests for detection of 
anal high-risk human papillomavirus
Livia Bravo Maia[1], Larissa Cardoso Marinho[1], Anamélia Lorenzetti Bocca[1],  
Florêncio Figueiredo Cavalcante Neto[1], Lara Franciele Ribeiro Velasco[2],  
Patrícia Godoy Garcia Costa[2], Fabiana Pirani Carneiro[1]  
and Paulo Gonçalves de Oliveira[3]
[1]. Departamento de Patologia, Hospital Universitário de Brasília, Brasília, DF. [2]. Departamento de Biologia Molecular, Laboratório Sabin, Brasília, DF. 
[3]. Serviço de Coloproctologia. Hospital Universitário de Brasília, Brasília, DF.
ABSTRACT
Introduction: This study evaluated the level of concordance between hybrid capture II (HCII) and PapilloCheck® for the 
detection of high-risk human papillomavirus (HPV) in anal samples. Methods: Anal cell samples collected from 42 human 
immunodeficiency virus (HIV)+ patients were analyzed. Results: Considering only the 13 high-risk HPV types that are detectable 
by both tests, HCII was positive for 52.3% of the samples, and PapilloCheck® was positive for 52.3%. The level of concordance 
was 80.9% (Kappa = 0.61). Conclusions: Good concordance was observed between the tests for the detection of high-risk HPV.
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Human papillomavirus (HPV) tests can be very useful 
for improving the sensitivity of cytology to detect anal 
intraepithelial neoplasia (AIN) and in post-treatment follow-
up because of the tests’ excellent negative predictive value1,2. 
Different tests for the detection of high-risk HPV have been 
used to assess cervical specimens3. The hybrid capture II 
(HCII) test (QIAGEN, Gaithersburg, MD, USA) is approved 
by the US Food and Drug Administration (FDA) and is used to 
validate new high-risk HPV tests for cervical screening. Two 
different probe cocktails are used; one comprises probes for 
the five low-risk genotypes, 6, 11, 42, 43 and 44, and the other 
contains probes for the 13 high-risk genotypes, 16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59 and 684. The test recognizes all 
13 HPV types, which are classified as class I carcinogenic with 
respect to cervical cancer by the World Health Organization 
(WHO)5. However, this test has certain limitations, namely that 
it distinguishes between the high-risk and low-risk groups but 
does not permit the identification of specific HPV genotypes or 
multiple HPV infection6. In addition, cross-reactivity between 
the two probe cocktails has been observed7. Relative light 
unit (RLU)/cut-off (CO) values are considered to provide a 
semiquantitative estimate of viral load4. 
The PapilloCheck® test (Greiner Bio-One, Frickenhausen, 
Germany) is a polymerase chain reaction (PCR)-based 
deoxyribonucleic acid (DNA) microarray system that allows 
the genotyping of 24 different HPV types (six low-risk and 18 
high-risk types). The high-risk types include the 13 high-risk 
types detected by HCII and types 73, 82, 53, 66 and 70. The 
low-risk types include types 6, 11, 40, 42, 43 and 44/558. The 
results are expressed qualitatively and semiquantitatively by 
signal-to-noise ratio (SNR) for 24 low- and high-risk HPV types 
simultaneously. The PapilloCheck® test distinguishes HPV types 
and multiple HPV infection and provides the SNR value for each 
type8. The PapilloCheck® test has been considered a reliable 
screening test for HPV detection and typing9,10. Because HCII and 
PapilloCheck® are commercially available and widely used for 
routine diagnosis, this study evaluated their level of concordance 
for the detection of high-risk HPV in anal cytological samples.
This study included 42 human immunodeficiency virus 
(HIV)-positive patients (30 men and 12 women) older than 
18 years with no visible lesions as observed in external visual 
examinations. An endocervical brush was introduced 4cm into 
the anal canal, rotated five times, removed and then agitated in 
the transport solution (PapilloCheck® collection medium and 
hc2 DNA collection device) provided by the manufacturer. The 
resulting cell suspension was stored dry at 4-8°C. Two samples 
were collected from each patient. To avoid false differences 
between the tests based on the order of collection, this was 
alternated between patients.
This study was approved by the Ethics in Research 
Committee of Brasilia University.
The HCII test was performed according to the manufacturer’s 
instructions8. The probe cocktail for the detection of the 13 high-
risk genotypes was used. A relative light unit/cut-off (RLU/CO) 
value of 1.0 or greater was considered positive for high-risk 
HPV detection7.
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TABLE 1 - Frequency of concordant and discordant results between 
PapilloCheck® and HCII.
              HCII
PapilloCheck® positive negative Total
Positive 18 4 22
Negative 4 16 20
Total 22 20 42
HCII: hybrid capture II.
TABLE 2 - Relative light unit/cut-off ratio and signal-to-noise ratio 
values of the samples with concordant results in PapilloCheck® 
and HCII.



































HCII: hybrid capture II; RLU/CO: relative light unit/cut-off; SNR: 
signal-to-noise ratio.
The PapilloCheck® test was performed according to the 
manufacturer’s instructions. This test cannot distinguish 
between HPV-55 and HPV-44 due to cross-reactivity. Samples 
with an SNR greater than 20 were considered positive.
Statistical analysis was performed using GraphPad Prism 4 
(GraphPad Software, San Diego, CA). The level of concordance 
between the two tests was determined using Cohen’s Kappa 
coefficient. For multiple infection samples, the SNR values of 
each identified type were added. Statistical significance was 
assigned to p < 0.05.
The HCII test yielded positive results for 22/42 (52.3%) 
samples. Considering only the 13 high-risk HPV types that 
can be detected by both tests, PapilloCheck® was positive for 
22/42 (52.3%) samples. All 13 high-risk HPV types that can 
be detected by both tests were detected, except for HPV 33. 
Multiple HPV infection was detected in 8/42 (19%) samples. 
The number of concordant results was 34/42 (80.9%), with a 
Kappa coefficient value of 0.61, indicating good agreement 
(Table 1). Of the 8/42 discordant samples, four tested positive 
by PapilloCheck® but negative by HCII; the HPV types found 
in these samples by PapilloCheck® were HPV 35, 56 and 68, 
all of which are high-risk HPV types included in the 13 high-
risk HPV-probe set of HCII. The other four discordant samples 
tested positive by HCII but negative by PapilloCheck®. The 
PapilloCheck® assay was fully negative for three of these 
samples (i.e., none of the 24 HPV types that are detectable by 
PapilloCheck® was observed), but one sample tested positive for 
HPV 82, a high-risk HPV type detected only by PapilloCheck® 
and not included in the 13 high-risk HPV-probe set of HCII.
The median (minimum-maximum) RLU/CO ratio was 
1.03 (0.26-572.6), and the median (minimum-maximum) SNR 
value was 21.9 (0-2197). In the discordant samples, the RLU/
CO values ranged from 0.3-16.52, and the SNR values ranged 
from 0-198.1. The RLU/CO and SNR values of all samples are 
shown in Tables 2 and 3.
Overall, 28/42 (66.7%) samples were positive for one or 
more of the HPV types that can be detected by PapilloCheck®. 
Of the HPV-positive samples, 27/42 (64.3%) had at least one 
high-risk HPV type. Multiple infection (more than one HPV 
subtype) was found in 19/42 (45.2%) samples. All high-risk 
HPV types were detected, except for HPV 33 and 73. The most 
frequent high-risk subtype was HPV 16 (7/42, 16.7%), and the 
most frequent low-risk subtype was HPV 44/55 (8/42, 19%).
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TABLE 3 - Relative light unit/cut-off ratio and signal-to-noise ratio 
values of the samples with discordant results between PapilloCheck® 
and HCII.









HCII: hybrid capture II; RLU/CO: relative light unit/cut-off; SNR: 
signal-to-noise ratio.
A high level of agreement between the PapilloCheck® 
and hybrid capture II tests for HPV detection has been shown 
for cervical samples9-11. In a previous study in which 44% of 
the samples were CIN2+/HSIL, the sensitivity, specificity, 
positive predictive value (PPV) and negative predictive value 
(NPV) of the PapilloCheck® and HCII tests for CIN2+/HSIL 
histology detection were 96%, 40%, 61% and 91% and 95%, 
42%, 61% and 90%, respectively. None of the comparisons of 
sensitivities, specificities, PPVs or NPVs showed statistically 
relevant differences between these tests, and a good sensitivity 
and NPV (greater than 90%) were observed for both9. Consistent 
with these results, the present study demonstrated an 80.9% 
concordance between PapilloCheck® and HCII for the detection 
of the 13 high-risk HPV types that are detectable by both tests 
in anal cytological samples.
For cervical samples, the concordance between these tests 
depends on the viral load. Agreement increases with viral load, 
and a significant number of discordant results were observed for 
samples with an RLU/CO ratio value between 1.0 and 5.010,12. 
The proportion of both false negativity and false positivity 
increased considerably with RLU value proximity to the CO 
value (i.e., 1.0 RLU/CO), suggesting that these samples should 
be retested13. Similarly, among the values obtained with the 
PapilloCheck® test, samples with discordant results showed 
low SNR values (≤ 25)12. Regarding the discordant results of 
the present study, the types detected by PapilloCheck® but not 
by HCII were HPV 35, 56 and 68, all of which were included 
in the 13 high-risk HPV-probe set of the HCII test. Didelot 
et al.11 also observed one sample in which HPV 16 was detected 
by the PapilloCheck® test and sequencing, but the sample tested 
negative for high-risk HPV infection by hybrid capture11. In the 
discordant results of the present study, the SNR values observed 
by PapilloCheck® were not sufficiently low (21, 29, 91.1 and 
198.1) to explain the negative results of the HCII test, and only 
one sample had an SNR value < 25. For samples that tested 
positive by HCII and negative by PapilloCheck®, the RLU/CO 
ratio values were low (1.38, 3.52, 4.19 and 16.52), and only 
one RLU/CO ratio value was > 5. Certain samples might have 
tested positive by HCII and negative by PapilloCheck® due to 
cross-reactivity with HPV types other than those theoretically 
detected by both tests. Poljak et al.7 showed that the HCII high-
risk probe cocktail detects at least 15 HPV genotypes that are 
not included in the current HCII high-risk probe cocktail7.
The HCII test has not been validated as a quantitative test, 
although RLU/CO values can be considered to provide good 
estimates of HPV load14. In the PapilloCheck® test, as in the HCII 
test, the viral load is expressed semiquantitatively using SNR 
values. For cervical samples, HPV load evaluation is important 
because of its association with lesion severity and persistence, 
but to the best of our knowledge, there are no studies evaluating 
the possible role of HPV load as a marker in anal samples14,15.
In conclusion, the PapilloCheck® and HCII tests have a 
good concordance level for the detection of the 13 high-risk 
HPV types that are detectable by both tests in anal cytological 
samples.
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